- Home
- AKA vs ALXO Comparison
AKA vs ALXO Comparison
Compare AKA & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKA
- ALXO
- Stock Information
- Founded
- AKA 2018
- ALXO 2015
- Country
- AKA United States
- ALXO United States
- Employees
- AKA N/A
- ALXO N/A
- Industry
- AKA Catalog/Specialty Distribution
- ALXO Biotechnology: Pharmaceutical Preparations
- Sector
- AKA Consumer Discretionary
- ALXO Health Care
- Exchange
- AKA Nasdaq
- ALXO Nasdaq
- Market Cap
- AKA 110.4M
- ALXO 93.7M
- IPO Year
- AKA 2021
- ALXO 2020
- Fundamental
- Price
- AKA $13.95
- ALXO $1.54
- Analyst Decision
- AKA Strong Buy
- ALXO Strong Buy
- Analyst Count
- AKA 4
- ALXO 6
- Target Price
- AKA $25.75
- ALXO $3.30
- AVG Volume (30 Days)
- AKA 61.7K
- ALXO 532.6K
- Earning Date
- AKA 11-05-2025
- ALXO 11-10-2025
- Dividend Yield
- AKA N/A
- ALXO N/A
- EPS Growth
- AKA N/A
- ALXO N/A
- EPS
- AKA N/A
- ALXO N/A
- Revenue
- AKA $598,107,000.00
- ALXO N/A
- Revenue This Year
- AKA $7.23
- ALXO N/A
- Revenue Next Year
- AKA $4.04
- ALXO N/A
- P/E Ratio
- AKA N/A
- ALXO N/A
- Revenue Growth
- AKA 7.67
- ALXO N/A
- 52 Week Low
- AKA $7.00
- ALXO $0.40
- 52 Week High
- AKA $26.79
- ALXO $2.27
- Technical
- Relative Strength Index (RSI)
- AKA 59.53
- ALXO 47.86
- Support Level
- AKA $13.49
- ALXO $1.53
- Resistance Level
- AKA $15.38
- ALXO $1.90
- Average True Range (ATR)
- AKA 1.32
- ALXO 0.16
- MACD
- AKA 0.16
- ALXO -0.05
- Stochastic Oscillator
- AKA 67.45
- ALXO 13.61
About AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.